Fate Therapeutics (FATE) Stock Price, News, Quotes-Moomoo

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Presents 6-Month Follow-Up Data On First Patient Treated In Phase 1 Autoimmunity Study With Fludarabine-Free Conditioning And FT819 Off-The-Shelf, 1XX CAR T-Cell Product Candidate At ACR Convergence
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies
Patient Treated with Fludarabine-free Conditioning a...

Stock_Drift

Nov 9 13:03

$Fate Therapeutics (FATE.US)$

Jaguar8

Nov 9 12:31

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Fate Therapeutics (NASDAQ: FATE) presented initial clinical and preclinical data for FT825/ONO-8250, a CAR T-cell therapy targeting HER2 in advanced solid tumors. The Phase 1 study's first low-dose cohort of three heavily pre-treated patients showed favorable safety outcomes with ...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

FATE Fate Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target